Purpose: To evaluate by in vivo laser scanning confocal microscopy (LSCM) the corneal findings in moderate-to-severe dry eye patients before and after treatment with topical corticosteroid and to associate the confocal findings to the clinical response. Methods: Fifty eyes of 50 patients with moderate-to-severe dry eye were included in this open label, masked study. Exclusion criteria were any systemic or ocular condition (other than dry eye) and any systemic or topical treatment (except artificial tears), ongoing or performed in the previous 3 months, with known effect on the ocular surface. All patients were treated with loteprednol etabonate ophthalmic suspension 0.5% q.i.d. for 4 weeks. Baseline and follow-up (day 30±2) visits included Ocular Surface Disease Index (OSDI) questionnaire, full eye exam and central cornea LSCM. We compared data obtained before and after treatment and looked for associations between baseline data and steroids-induced changes. Basing on the previously validated OSDI Minimal Clinically Important Difference, we re-analyzed the baseline findings comparing patients clinically improved after treatment (CIAS) to patients not clinically improved (NCIAS for clinical response to treatment with steroids. We think that this approach might contribute to bridge the current gap between the pathogenesis-driven classification and the severity-driven management of dry eye. Detailed response to original reviews
Ln54, CHANGED: "Data for superficial and basal epithelial cell density, anterior, posterior, and activated keratocyte density, 8 sub-basal dendritic cell density (DCD), 7, 10, 14, 15 and sub-basal nerve length and tortuosity were acquired."
Ln 58, CHANGED: "Images selection and analysis were performed by a single masked investigator, following previously published and validated procedures. 7 , 10 "
Ln 62, ADDED: "Epithelial (superficial and basal) and stromal (anterior and posterior) cells were counted at the first and at the last clearly visible epithelial and stromal layer. Activated keratocytes were defined as stomal cells with hyper-reflective ovoid or multilobate nuclei. 8, 16, 17 "
Ln 65, CHANGED: "The total length of nerves in each image, defined as the sum of the length of all the nerve fibres within a frame, was calculated using the segmented line drawing tool of ImageJ software (available in the public domain at http://imagej.nih.gov/ij/)".
How well does DCD actually reflect the inflammatory state at the ocular surface? How closely does a change in DCD parallel other readouts of ocular inflammation? What is the biological
significance of a change in DCD in the setting of dry eye? If using DCD as a read out for proinflammatory activity has been validated, then it needs to be clearly described.
If DCD provides a readout for proinflammatory activity, It is somewhat counterintuitive that an increase in DCD would be noted in patients that experience clinical significant improvements following treatment with steroid. Please discuss.
Ln 135, ADDED: "Previous reports on sub-basal dendritic cells, in particular, interpreted as
Langerhans antigen-presenting cells, 14 showed increased DCD in inflammatory conditions 4, 31, 32 and correlations between DCD and both corneal immunohistochemistry analysis 15 and tear fluid inflammatory cytokines concentration. 10, 33 "
Ln 140, ADDED: "To the best of our knowledge, this is the first research describing steroid-related prompt change of a largely studied, validated, and repeatable in vivo confocal inflammatory parameter."
We agree with your last observation. Our dye eye patients showed a decrease in DCD after therapy with steroid. Thank you for your appreciation.
The authors did acknowledge the important study limitation of not having a control group.
However, the following comments and suggestions need to be addressed:
Abstract
Results section: Please clarify the correlation between baseline DCD and OSDI and DCD steroid-related changes. How were they calculated? Were the correlations determined by using the differences between baseline and follow-up OSDI and DCD changes or the absolute end point values? Please state a positive or negative correlation for clarity.
We clarified correlation findings both in the abstract and in the manuscript.
Abstract, ADDED: "(r=-0.44, P<0.05 and r=-0.70, P<0.01, respectively; Spearman)" Ln98, CHANGED: "The DCD baseline values were significantly correlated with both OSDI and DCD steroid-related changes, defined as V1-baseline values (r=-0.44, P<0.05 and r=-0.70, P<0.01, respectively; Spearman)."
Methods
Line 24: Did the authors intended to use the term "afferent"? Suggest replacing with "referred" to describe patients being directed to study center.
Done as suggested, thank you. 
Study design and procedures

NCIAS?
The Delphi Panel grading was used to include the patients ("We consecutively recruited 50 patients (41 women and 9 men; average ± standard deviation age 54.6±10.1 years, range 35-77 years) with moderate-to-severe dry eye…").
In order to assess MCID, using SGA-related data, thresholds were set on the basis of the OSDI score of each patient.
Methods, ln81, ADDED: "According to Miller KL et al. 19 "Subject Global Assessment" data, MCID thresholds were set at 6.1, 5.3, and 13.4 for 13<OSDI<22 points, 23<OSDI<32 points, and 33<OSDI<100 points, respectively."
Results, ln102, ADDED: "Applying to our study population the OSDI MCID, 19 This kind of analysis would be an elegant approach to be included in future more robust studies.
Our statistician warned us not to include that in the present analysis, because we would have several independent variables and this is a pilot study without an adequately calculated sample size.
The results indicate that baseline DCD was significantly higher in CIAS vs. NCIAS patients.
Was there a difference in V1 DCD or a change in DCD from baseline to V1 between these two groups of patients that might explain for improvement in OSDI scores?
Were differences in V1 clinical and confocal data between CIAS and NCIAS evaluated?
Ln106, ADDED: "At V1, DCD was significantly decreased in CIAS (P<0.01, paired samples t-test)
but not in NCIAS patients, with no further difference between the 2 groups (65.4±43.9 vs 61.8±47.8, not significant; independent samples t-test)." We reformatted the figure as suggested by the Managing Editor.
If you feel that is essential to highlight typical findings in the figure, we will do that. We respectfully prefer to avoid adding symbols that could interfere with clinical interpretation of the images. Several images of typical confocal appearance of DC and nerves have already been published by our group and by other researchers and a number of them are referenced in this paper.
Moreover, this paper has been submitted to be included in a "Dry Eye" special issue; the same issue will include an invited contribution where we will show typical confocal findings in dry eye.
If you agree, we only changed the figure legend. Table 2 -gender P-value indicates "n.d." with no explanation in table legend for "n.d." Table 2 , ADDED: n.d.: not determined
Discussion
The important conclusions from the study are based primarily on determination of DCD.
Please discuss whether the DCD findings in this study population are comparable to previous publications of DCD in normal and/or dry eye patients. Is the DCD valid based on previous publications? Please discuss.
Ln153, ADDED: "In our dry eye patients, the mean baseline DCD was comparable with the higher range of previously published LSCM data (139 vs 56-127cells/mm 2 ). We agree that this is an important parameter to be included in well-designed clinical trials, but the protocol of this pilot study did not include specific procedures to assess compliance to therapy. We simply asked to patients at V1 if they had regularly instilled the therapy and we have had positive feedbacks from all the patients. However, we have no reasons to hypothesize a lower compliance to therapy in patients with baseline lower DCD. Key words: dry eye, inflammation, corticosteroids, cornea, confocal microscopy Dry eye syndrome is a common ocular disorder, with a prevalence of 5% to 30% of the adult population. 1 Inflammation of the ocular surface is a major pathogenic mechanism in the etiology of dry eye, and it is potentially an important biomarker of this multifactorial disease. 2 The management of inflammation in moderate-to-severe dry eye includes the use of topical corticosteroids, 3 with level I evidence of effectiveness published for a number of formulations. 3 In vivo laser scanning confocal microscopy (LSCM) has a resolution comparable to histological techniques and provides a non-invasive tool that allows the study of the living ocular surface structures at the cellular level. This technology has been applied to several ocular surface conditions, 4 including dry eye. 5, 6 LSCM application to dry eye recently showed 2 main
advances: new opportunities to analyze simultaneous information from the whole ocular surface morpho-functional unit, 6, 7 and promising results in the study of inflammation [7] [8] [9] and in the monitoring of the response to therapy. [10] [11] [12] Specifically, the effectiveness of LSCM in measuring changes related to dry eye disease and related to treatment 5, 6, [10] [11] [12] is of interest with the potential to be able to provide new clinical applications.
The purpose of the present study was two-fold. First, we evaluated by corneal LSCM the changes related to treatment with topical corticosteroids in moderate-to-severe dry eye patients.
Second, we analyzed the LSCM findings in patients clinically improved and not clinically improved with the treatment.
METHODS
Patients
This study adhered to the tenets of the Declaration of Helsinki, and all of the subjects provided written informed consent before examination.
We recruited 50 consecutive patients (41 women and 9 men; average ± standard deviation age 54.6±10.1 years, range 35-77 years) with moderate-to-severe dry eye who were referred to our general clinic. Each diagnosis was made according to the modified dry eye severity grading classification of the Delphi Panel Report. 2 Inclusion criteria were dry eye symptoms for more than 6 months, reduced break up time (BUT < 10 sec), reduced Schirmer score (<10 mm/5 min), and positive corneal and conjunctival staining. Exclusion criteria were trauma or ocular surgery in the previous 6 months, any systemic or ocular disease (other than dry eye), and any systemic or topical treatment with a known effect on the ocular surface (except artificial tears) ongoing or performed in the previous 3 months.
Study Design and Procedures
The study protocol included a baseline visit, V0, and a follow-up visit, V1, 28 -32 days later.
Unscheduled visits were performed when due to worsening symptoms. All enrolled patients were 
Image Analysis
Data for superficial and basal epithelial cell density, anterior, posterior, and activated keratocyte density, 8 sub-basal dendritic cell density (DCD), 7, 10, 14, 15 and sub-basal nerve length and tortuosity were acquired. Each LSCM parameter was obtained by selecting the best quality image from each of the 3 antero-posterior scans and averaging the results. Image selection and analysis were performed by a single masked investigator, following previously published and validated procedures. 7, 10 Briefly, cell density was determined through the manual cell counting procedure present in the software, taking into consideration the whole area marked as available for the cell count. Cells that were partially within the area analyzed were counted only along the right and lower margins. Epithelial (superficial and basal) and stromal (anterior and posterior) cells were counted at the first and at the last clearly visible epithelial and stromal layer. Activated keratocytes were defined as stromal cells with hyper-reflective ovoid or multilobate nuclei. 8, 16, 17 Results were expressed in cells per square millimeter. The total length of nerves in each image, defined as the sum of the length of all the nerve fibres within a frame, was calculated using the segmented line drawing tool of ImageJ software (available in the public domain at http://imagej.nih.gov/ij/). The tortuosity was evaluated according to grading performed by comparison with the reference images.
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For each parameter showing a significant difference between V1 and V0, 15 confocal images were randomly selected and re-analyzed by a second independent masked investigator in order to assess the inter-observer agreement.
Statistical Analysis
Data derived from the worst eye, defined as the one with the lower BUT, were used for statistical analysis. All of the data were expressed as the average ± standard deviation. We compared baseline clinical and confocal data to V1 data using the t-test for repeated measures. K coefficient was used to test inter-observer agreement. We also tested correlations between baseline data and steroid-induced changes with Spearman's correlation coefficient.
Based on the previously validated OSDI Minimal Clinically Important Difference (MCID), 19 we divided the study populations into clinically improved after steroids (CIAS) and not clinically improved after steroids (NCIAS). According to Miller KL et al. 19 "Subject Global Assessment" data, MCID thresholds were set at 6.1, 5.3, and 13.4 for 13<OSDI<22 points, 23<OSDI<32
points, and 33<OSDI<100 points, respectively. We re-analyzed the baseline findings, comparing CIAS to NCIAS groups with the independent samples t-test. 
RESULTS
No adverse events, including clinically significant intra-ocular hypertension, were observed during topical steroid therapy. No unscheduled visits due to worsening symptoms were performed during the study period. At V1, all patients referred good tolerability and good compliance to the treatment.
OSDI score, fluorescein and lissamine green staining, DCD, and hyper-reflective keratocytes density all significantly decreased from baseline to V1 (Table 1) . However, corticosteroid treatment did not induce significant differences in epithelial and keratocyte cell densities, subbasal nerve length, or nerve tortuosity. Based on the concept that inflammation is a key component of the pathogenesis of dry eye, several anti-inflammatory therapies, including topical corticosteroids, play a role in treatment of moderate-to-severe dry eye. 3, 21, 22 Loteprednol etabonate efficacy in this disease has already been reported in both research and clinical settings. [23] [24] [25] Moreover, this is a site-active corticosteroid that undergoes a predictable and relatively rapid metabolism to an inactive metabolite. This characteristic improves the safety profile, reduces the risk of increasing intraocular pressure, and makes it a good candidate for use in inflammatory ocular surface conditions. 23 In clinical practice, the current severity-driven grading of dry eye provides poor direct information on inflammatory activity. The simultaneous evaluation of symptoms (maybe related to inflammation), tears secretion and stability (may be causes of inflammation), and superficial epithelial changes (may be caused by inflammation) seems to provide a complex of information more suitable for disease classification, i.e. in hypo-secretive and hyper-evaporative forms, than for assessment on inflammation activity. To study the role of immunity and inflammation in patients, tools are needed to visualize immune cells in vivo. 26 In the last few years, LSCM has shown potentials in analyzing dry eye-related inflammation in several ocular surface components, [4] [5] [6] [7] including the corneal epithelium 27 and stroma, 8 conjunctiva, 9, 28 and meibomian glands. 29 It also has the ability to detect changes due to treatment. 10, 30 In this study, sub-basal dendritic cells and hyper-reflective activated stromal keratocytes significantly decreased after treatment with loteprednol. Both of these cell types have previously been hypothesized to be signs of inflammation in confocal images. 4-8, 10, 26, 31 Previous reports on sub-basal dendritic cells, in particular, interpreted as Langerhans antigen-presenting cells, 14 showed increased DCD in inflammatory conditions 4, 31, 32 and correlations between DCD and both corneal immunohistochemistry analysis 15 and tear fluid inflammatory cytokines concentration.
10, 33
The inter-observer repeatability of these cells assessment, already tested in patients and healthy subjects, 10, 26, 31 has been confirmed by our results. To the best of our knowledge, this is the first research describing steroid-related prompt change of a largely studied, validated, and repeatable in vivo confocal inflammatory parameter.
Our results contribute to open interesting prospects for the use of LSCM as a non-invasive biomarker to assess ocular surface inflammation. We feel that our most interesting LSCM results may be the correlation between baseline DCD and steroid-related OSDI changes and the baseline difference in DCD between CIAS and NCIAS patients. In order to assess therapy-related clinically significant improvement of symptoms, we used the previously validated OSDI MCID 19 . The MCID is defined as "the smallest difference in score in that domain of interest which subjects perceive as beneficial and which would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient's management." 34 We think that this instrument, when applied to ocular surface disease symptoms and dry eye patients, may represent an important progress in both clinical management and clinical research endpoints' development.
In our dry eye patients, the mean baseline DCD was comparable with the higher range of previously published LSCM data (139 vs 56-127cells/mm 2 ). This preliminary research has important limitations, including the lack of a control group, but these findings suggest the need for future studies, using an appropriate more robust study design, planned to test the predictive value of DCD for clinical response to treatment with steroids. We think that this approach might have great potential to enable new clinical applications of LSCM and, above all, to help bridge the current gap between the pathogenesis-driven classification and the severity-driven management of dry eye.
